



## Multiple Sclerosis

### Syndicated Thought Leader Insight

---

## ***Thought Leader Insight & Analysis Report*** **Multiple Sclerosis Q2 2011**

<b>Therapeutic Class:</b>	CNS Disorders
<b>Focus Area:</b>	Multiple Sclerosis
<b>Specialty/Location:</b>	Neurologists/N. America
<b>Number of Interviews:</b>	6
<b>Number of Pages:</b>	134
<b>Publication Date:</b>	May 2011
<b>Principal Authors:</b>	Tricia L. Hanlon Kim Grant Jeffrey D. Berk, Ph.D., MBA
<b>Product Code:</b>	MAIMQ211-13
<b>Pricing:</b>	\$7,500
<b>Order Info:</b>	www.medpredict.com or call (513) 271-1924

#### **Abstract:**

Multiple Sclerosis Thought Leader Panel #13 highlights a series of interviews conducted with our international panel of experts in May 2011, around the time of AAN 2011.

The topics of conversation centered on Biogen's too good to be true BG-12 data, Teva's too bad to be true laquinimod data, whether a JC diagnostic can save Tysabri, very strong ocrelizumab results, and other controversies related to the multiple sclerosis development pipeline.

**Full transcripts of six qualitative interviews with neurologists are included with this report.**

**Drugs/Companies Discussed:**

Acorda / Elan / Biogen	Ampyra / Fampyra	dalfampridine; 4-aminopyridine
Bayer-Schering / Genzyme	Campath	alemtuzumab
Biogen-Idec	Avonex	interferon beta-1a PEGylated interferon beta-1a
	Panaclar	BG-0012 (fumarate)
Biogen-Idec / Elan	Tysabri	natalizumab
Biogen-Idec / Genentech / Roche	Rituxan / MabThera	rituximab ocrelizumab
Boehringer-Ingelheim / Exelixis		XL-9953
Coronado		CNDO-201
GSK		firategrast
GSK / Genmab		ofatumumab
Merck-Serono	Mylinax	cladribine
Novartis Novartis / Kyorin	Gilenya	fingolimod BAF-312
Ono		ONO-4641
PDL/Biogen/Abbott	Zenapax	daclizumab
Roche / Actelion		ponesimod; ACT-128800
Sanofi-Aventis		teriflunomide
Teva / Sanofi-Aventis	Copaxone	glatiramer acetate
Teva		laquinimod

## Table of Contents

### Executive Summary 3

### Key Findings 14

<b>S1P Receptor Agonists</b> .....	<b>14</b>
Gilenya; fingolimod (Novartis) .....	14
XL-9953 (Boehringer-Ingelheim / Exelixis) .....	19
BAF-312 (KRP-203, Kyorin / Novartis) .....	20
Ponesimod / ACT-128800 (Actelion) .....	20
ONO-4641 (Ono) .....	23

<b>Oral Immunomodulators</b> .....	<b>24</b>
Panaclar; BG-00012; BG-12; fumarate (Biogen-Idec).....	24
laquinimod (Teva) .....	33
teriflunomide (Sanofi-Aventis) .....	40

<b>Oral Cell Cycle Arrest</b> .....	<b>48</b>
Mylinax (cladribine; Merck-Serono) .....	48

<b>VLA-4</b> .....	<b>58</b>
Tysabri; natalizumab (Biogen / Elan).....	58
firategrast (GlaxoSmithKline).....	62

<b>B-Cell Inhibitors</b> .....	<b>63</b>
CD20 .....	63
Ocrelizumab (Roche / Genentech / Biogen-Idec).....	63
Ofatumumab (Genmab / GSK) .....	70
CD52 .....	73
Campath; anti-CD-52; alemtuzumab (Genzyme / Sanofi-Aventis / Bayer-Schering).....	73

<b>Interferon / Glatiramer Acetate</b> .....	<b>76</b>
Avonex (Interferon beta 1A; Biogen-Idec) .....	76
Betaseron (IFN beta 1b; Bayer-Schering) .....	76

<b>Anti-CD-25 (Anti-IL-2)</b> .....	<b>76</b>
Zenapax (daclizumab; PDL Biopharma/Biogen/Abbott).....	76

<b>Augment Functional Reserves</b> .....	<b>78</b>
Ampyra / Fampyra; dalfampridine (Acorda / Elan / Biogen) .....	78

<b>Vaccines / Immune Tolerance</b> .....	<b>79</b>
Tovaxin (Opexa) .....	79
CNDO-201 (Coronado).....	80

### Thought-Leader Discussions 82

<b>Interview CNS02558</b> .....	<b>82</b>
<b>Interview CNS02559</b> .....	<b>91</b>
<b>Interview CNS02560</b> .....	<b>101</b>
<b>Interview CNS02561</b> .....	<b>109</b>
<b>Interview CNS02562</b> .....	<b>117</b>
<b>Interview CNS02563</b> .....	<b>127</b>